Patents Assigned to Mor Research Applications
-
Publication number: 20090198324Abstract: Disclosed are methods for treatment of cardiac valve including augmenting a cardiac leaflet with the help of a ring associated with a membrane. Also disclosed are methods for treatment of cardiac valves including augmenting the tissue surrounding a cardiac valve, for example with the help of a tubular or annular implant, allowing relocation of the valve. In embodiments, the methods of the present invention improve leaflet coaptation, which in embodiments is useful for treating conditions such as ischemic mitral regurgitation. Also disclosed are devices useful for implementing the methods of the present invention.Type: ApplicationFiled: May 21, 2007Publication date: August 6, 2009Applicant: Mor Research Applications Ltd.Inventor: Boris Orlov
-
Patent number: 7524498Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.Type: GrantFiled: September 12, 2007Date of Patent: April 28, 2009Assignees: CureTech Ltd., Mor-Research Application Ltd.Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
-
Publication number: 20090105812Abstract: A device is presented for assisting an insufficient aortic valve. The device is configured as an auxiliary valve and comprises a resilient deformable sleeve-like valve, deformation of the sleeve-like valve shifting the valve between its closed and opened positions.Type: ApplicationFiled: October 21, 2008Publication date: April 23, 2009Applicants: Yeda Research & Development Ltd. The Weizmann Institute of Science, Mor Research Applications Ltd.Inventors: Boris Levin, Alexander Rejabek, Alexander Lerner, Sofia Levin
-
Publication number: 20090010947Abstract: A method of transforming red microalgae is provided. The method is effected by: (i) culturing red microalgae cells under predetermined light/dilution conditions to thereby generate competent red microalgae cells; and (ii) introducing at least one exogenous polynucleotide into said competent red microalgae cells, thereby transforming the red microalgae.Type: ApplicationFiled: August 4, 2005Publication date: January 8, 2009Applicants: Mor Research Applications Ltd., Ben Gurion University of the Negev Research and Development AuthorityInventors: Shoshana Arad, Miri Lapidot, Yacob Weinstein, Ron Dagan
-
Publication number: 20090004276Abstract: A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions.Type: ApplicationFiled: June 11, 2008Publication date: January 1, 2009Applicant: Mor Research Applications Ltd.Inventors: Noah Ben-Shalom, Zvi Nevo, Abraham Patchornik, Dror Robinson
-
Publication number: 20080287380Abstract: Antisense oligonucleotides against cPLA2 are provided, which are capable of inhibiting cPLA2 expression as well as superoxide production, especially in phagocytes. These antisense oligonucleotides are powerful agents for the treatment of inflammatory conditions, in particular arthritis, as well as in neurodegenerative diseases. The antisense oligonucleotides or compositions comprising the same may be used in methods of treatment of such diseases.Type: ApplicationFiled: April 17, 2005Publication date: November 20, 2008Applicants: Mor Research Applications Ltd., Ben-Gurion University of the Negev Research and Development AuthorityInventor: Rachel Levy
-
Publication number: 20080175855Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.Type: ApplicationFiled: December 14, 2007Publication date: July 24, 2008Applicants: Curetech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Annat Raiter, Leah Klapper
-
Publication number: 20080138331Abstract: A method is described for the diagnosis of an ovarian or endometrial tumor or for a prognosis, characterized in that the L1 level is determined in a patient sample, preferably via an anti L1 antibody, the presence of L1 being an indication of the presence of an ovarian or endometrial tumor or a predisposition for such a tumor. Furthermore, methods for treating of ovarian or endometrial tumors are provided.Type: ApplicationFiled: October 2, 2007Publication date: June 12, 2008Applicants: Mor Research Applications, Ltd., Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Peter Altevogt, Mina Fogel
-
Publication number: 20080051440Abstract: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows am efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.Type: ApplicationFiled: August 3, 2007Publication date: February 28, 2008Applicant: Mor Research Applications Ltd.Inventor: Nir Barak
-
Publication number: 20080051439Abstract: Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.Type: ApplicationFiled: August 3, 2007Publication date: February 28, 2008Applicant: Mor Research Applications Ltd.Inventor: Nir Barak
-
Patent number: 7332582Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.Type: GrantFiled: November 19, 2004Date of Patent: February 19, 2008Assignees: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
-
Patent number: 7329639Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.Type: GrantFiled: April 27, 2006Date of Patent: February 12, 2008Assignees: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Annat Raiter, Leah Klapper
-
Publication number: 20080025980Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.Type: ApplicationFiled: September 12, 2007Publication date: January 31, 2008Applicants: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Steven Jones, Leah Klapper
-
Publication number: 20080003306Abstract: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.Type: ApplicationFiled: August 3, 2007Publication date: January 3, 2008Applicant: Mor Research Applications Ltd.Inventor: Nir Barak
-
Publication number: 20080004254Abstract: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.Type: ApplicationFiled: August 3, 2007Publication date: January 3, 2008Applicant: Mor Research Applications Ltd.Inventor: Nir Barak
-
Publication number: 20080004322Abstract: Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.Type: ApplicationFiled: August 3, 2007Publication date: January 3, 2008Applicant: Mor Research Applications Ltd.Inventor: Nir Barak
-
Publication number: 20080004324Abstract: Methods for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed.Type: ApplicationFiled: August 3, 2007Publication date: January 3, 2008Applicant: Mor Research Applications Ltd.Inventor: Nir Barak
-
Patent number: 7122372Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.Type: GrantFiled: April 9, 2004Date of Patent: October 17, 2006Assignees: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Annat Raiter, Leah Klapper
-
Publication number: 20060210573Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.Type: ApplicationFiled: April 27, 2006Publication date: September 21, 2006Applicants: Curetech Ltd.,, Mor-Research Applications Ltd.,Inventors: Britta Hardy, Annat Raiter, Leah Klapper
-
Publication number: 20060166204Abstract: Specific PON1 and ACHE alleles segregate in linkage, forming an haplotype which directly correlates with higher susceptibility to develop Parkinson's Disease (PD). This PD-susceptibility haplotype is herein presented as a tool for predicting the risk of developing Parkinson's Disease and its severity, both for an individual and for the population in general. Thus, the present invention provides the use of said PD-susceptibility haplotype in diagnostic and screening methods.Type: ApplicationFiled: September 24, 2003Publication date: July 27, 2006Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, Mor Research Applications Ltd., Ben-Gurion University of Negev, Research & Development AuthorityInventors: Hermona Soreq, Liat Ben-Moyal, Boris Bryk, Alon Friedman